Tag: Fibrosis treatment

Over 45% of all deaths in industrialized nations are caused by fibrosis affecting various organs. The question of *what medication is used for fibrosis?* is central to treating this condition, and while there is no cure, FDA-approved drugs can slow its progression by targeting the underlying scarring process.

Chronic activation of transforming growth factor-β (TGF-β) is a key driver of fibrosis in many organs, including the liver, lungs, and kidneys. This critical role has led to the development of various therapeutic strategies, making the exploration of what drugs are anti TGFB a significant area of research.

Transforming growth factor-beta (TGF-β) is a multifunctional cytokine implicated in numerous disease processes, including fibrosis and cancer. As a result, therapeutic strategies targeting this pathway have been developed, with a primary focus on understanding **what drugs inhibit TGF-beta** and how they can be used for patient benefit.